Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | GCGR | P47871 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | HSPB1 | P04792 | 2/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3028123 | 0.88 | MAPT (0.41) | MAPTSMN1; SMN2RAB9ANPC1MEN1 | |
| SCHEMBL14666720 | 0.80 | POLB (0.33) | MEN1KMT2AALDH1A1POLB | |
| SCHEMBL3027955 | 0.79 | APP (0.34) | MAPTSMN1; SMN2GCGRMAPK14RAB9A | |
| SCHEMBL3032766 | 0.79 | PTGS2 (0.37) | MAPTPTGS1PTGS2 | |
| SCHEMBL3029825 | 0.77 | PTGS2 (0.42) | LMNAHTTPTGS1ALDH1A1L3MBTL1 | |
| SCHEMBL3012005 | 0.76 | HSD17B10 (0.41) | MAPTRAB9ANPC1MEN1KMT2A | |
| SCHEMBL3025036 | 0.75 | NR3C2 (0.48) | MAPTMEN1KMT2ALMNAALDH1A1 | |
| SCHEMBL14666664 | 0.74 | MAPK13 (0.32) | MAPTMAPK14MEN1KMT2AKDM4E | |
| SCHEMBL15049786 | 0.73 | MAOB (0.34) | MAPTSMN1; SMN2RAB9AMEN1KMT2A | |
| SCHEMBL3026812 | 0.73 | HSPB1 (0.37) | MAPTSMN1; SMN2RAB9ANPC1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2179994-B1 | FUSED BICYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORP (JP) | 2013-06-26 | — | — | EP | disclosed |
| US-8410166-B2 | Fused bicyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-04-02 | — | — | US | disclosed |
| US-8410166-B2 | Fused bicyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-04-02 | — | — | US | disclosed |
| US-8410166-B2 | Fused bicyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-04-02 | — | — | US | disclosed |
| US-20130029979-A1 | FUSED BICYCLIC COMPOUND | TAKAHASHI YOICHI (JP) | 2013-01-31 | — | — | US | disclosed |
| US-20130029979-A1 | FUSED BICYCLIC COMPOUND | TAKAHASHI YOICHI (JP) | 2013-01-31 | — | — | US | disclosed |
| US-8258131-B2 | Fused bicyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-09-04 | — | — | US | disclosed |
| US-8258131-B2 | Fused bicyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-09-04 | — | — | US | disclosed |
| US-20100204218-A1 | FUSED BICYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-08-12 | — | — | US | disclosed |
| US-20100204218-A1 | FUSED BICYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-08-12 | — | — | US | disclosed |
| EP-2179994-A1 | FUSED BICYCLIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-04-28 | — | — | EP | disclosed |
| EP-2179994-A1 | FUSED BICYCLIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-04-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130029979-A1 | FUSED BICYCLIC COMPOUND | NR3C2, NR3C1, MC2R | MAPT 4234/4885SMN1; SMN2 4664/4885GCGR 45/4885 |
| US-20100204218-A1 | FUSED BICYCLIC COMPOUND | NR3C2, NR3C1, MC2R | MAPT 4323/4885SMN1; SMN2 4805/4885GCGR 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.